Numis Securities reissued their buy rating on shares of Diurnal Group (LON:DNL) in a report published on Monday morning. Numis Securities currently has a GBX 185 ($2.49) target price on the stock.

Diurnal Group (LON DNL) opened at GBX 146.50 ($1.97) on Monday. Diurnal Group has a fifty-two week low of GBX 105 ($1.41) and a fifty-two week high of GBX 147 ($1.98).

In other Diurnal Group news, insider Martin Whitaker acquired 3,703 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The shares were acquired at an average price of GBX 135 ($1.82) per share, with a total value of £4,999.05 ($6,728.20).

ILLEGAL ACTIVITY WARNING: “Diurnal Group’s (DNL) “Buy” Rating Reiterated at Numis Securities” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at

About Diurnal Group

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with's FREE daily email newsletter.